Zhu Chen-Ying, Yu Pei-Han, Sun Qi, Hong De-Fei, Yang Chang, Naranmandura Hua
Department of Toxicology, School of Medicine and Public Health, Zhejiang University, Hangzhou 310058, China; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Department of Toxicology, School of Medicine and Public Health, Zhejiang University, Hangzhou 310058, China.
Pharmacol Res. 2025 Aug;218:107862. doi: 10.1016/j.phrs.2025.107862. Epub 2025 Jul 17.
Nuclear receptors (NRs) are ligand-activated transcription factors that function as metabolic sensors, integrating endogenous and xenobiotic signals to regulate gene networks controlling metabolism, immunity, and cellular homeostasis. Recent studies elucidated the pivotal roles of NRs (e.g., PPARs, LXRs, FXRs, ERs) in metabolic disorders (obesity, diabetes, metabolic dysfunction-associated steatotic liver disease) and certain cancer initiation/progression, particularly through their regulation of lipid metabolism, glucose homeostasis, and cholesterol balance. Fortunately, their activity involves the spatiotemporal dynamic coregulator interactions and pathway crosstalk also provide potential novel targets for therapeutic intervention. Although current drugs still face challenges in achieving tissue specificity and ligand selectivity for nuclear receptors, emerging approaches such as selective nuclear receptor modulators (SNRMs) and proteolysis-targeting chimeras (PROTACs) hold significant promise for treating metabolic and neoplastic disorders. In this review, we systematically summarize their precise regulation of lipid metabolism, glucose homeostasis, and cholesterol balance, which significantly influence disease pathogenesis and development. Additionally, future investigations employing integrated multi-omics approaches, advanced structural biology techniques, and AI-driven analyses will further unravel their precise regulatory mechanisms, paving the way for personalized therapeutic interventions, while critically evaluating their translational potential and clinical applications.
核受体(NRs)是配体激活的转录因子,作为代谢传感器发挥作用,整合内源性和外源性信号,以调节控制代谢、免疫和细胞稳态的基因网络。最近的研究阐明了核受体(如过氧化物酶体增殖物激活受体(PPARs)、肝X受体(LXRs)、法尼醇X受体(FXRs)、雌激素受体(ERs))在代谢紊乱(肥胖、糖尿病、代谢功能障碍相关脂肪性肝病)和某些癌症起始/进展中的关键作用,特别是通过它们对脂质代谢、葡萄糖稳态和胆固醇平衡的调节。幸运的是,它们的活性涉及时空动态共调节因子相互作用,并且信号通路串扰也为治疗干预提供了潜在的新靶点。尽管目前的药物在实现对核受体的组织特异性和配体选择性方面仍面临挑战,但诸如选择性核受体调节剂(SNRMs)和蛋白酶靶向嵌合体(PROTACs)等新兴方法在治疗代谢和肿瘤性疾病方面具有重大前景。在这篇综述中,我们系统地总结了它们对脂质代谢、葡萄糖稳态和胆固醇平衡的精确调节,这些调节对疾病的发病机制和发展有显著影响。此外,未来采用综合多组学方法、先进结构生物学技术和人工智能驱动分析的研究将进一步揭示它们的精确调节机制,为个性化治疗干预铺平道路,同时严格评估它们的转化潜力和临床应用。